Literature DB >> 23612688

Norcantharidin inhibits DNA replication and induces mitotic catastrophe by degrading initiation protein Cdc6.

Sansan Chen1, Pei Wan, Wen Ding, Fei Li, Chengwu He, Pengliang Chen, Hongwei Li, Zhiming Hu, Wanlong Tan, Jinlong Li.   

Abstract

Cdc6, an essential initiation protein for DNA replication, also participates in the ATR checkpoint pathway and plays a vital role in tumorigenesis. It is involved in the androgen receptor (AR) signal transduction and promotes the malignant progression of prostate cancer (PCa). In this study, we report that norcantharidin (NCTD) induces the degradation of Cdc6 in DU145 PCa cells and as a result, the assembly of pre-replication complexes (pre-RCs) was disturbed and DNA replication was inhibited. Furthermore, treatment with NCTD blocked ATR binding to chromatin and the cells progressed into mitosis under stress induced by hydroxyurea (HU), indicating that the ATR checkpoint was evaded. Aberrant mitosis and hence, apoptosis were also observed following treatment with NCTD. Finally, NCTD exerted strong synergistic cytotoxic effects in combination with another mitotic inhibitor, paclitaxel, [combination index (CI <1)]. These data suggest that NCTD not only inhibits DNA replication but also disables the ATR-dependent checkpoint pathway by inducing Cdc6 degradation, which leads to mitotic catastrophe in DU145 cells. These findings also provide a promising prospect for the combination treatment of paclitaxel and NCTD or Cdc6 deletion in PCa.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23612688     DOI: 10.3892/ijmm.2013.1359

Source DB:  PubMed          Journal:  Int J Mol Med        ISSN: 1107-3756            Impact factor:   4.101


  5 in total

1.  AAV-Mediated angiotensin 1-7 overexpression inhibits tumor growth of lung cancer in vitro and in vivo.

Authors:  Xinglu Chen; Sansan Chen; Nana Pei; Yingying Mao; Shengyao Wang; Renhe Yan; Na Bai; Andrew Li; Yanling Zhang; Hongyan Du; Baihong Chen; Colin Sumners; Jinlong Li; Hongwei Li
Journal:  Oncotarget       Date:  2017-01-03

2.  Norcantharidin Inhibits cell growth by suppressing the expression and phosphorylation of both EGFR and c-Met in human colon cancer cells.

Authors:  Peiju Qiu; Siwen Wang; Ming Liu; He Ma; Xuan Zeng; Meng Zhang; Lingling Xu; Yidi Cui; Huixin Xu; Yang Tang; Yanli He; Lijuan Zhang
Journal:  BMC Cancer       Date:  2017-01-13       Impact factor: 4.430

3.  Mir-26b inhibits growth and resistance to paclitaxel chemotherapy by silencing the CDC6 gene in gastric cancer.

Authors:  Bochao Zhao; Jiale Zhang; Xiuxiu Chen; Huimian Xu; Baojun Huang
Journal:  Arch Med Sci       Date:  2018-02-07       Impact factor: 3.318

4.  Cell Division Cycle 6 Promotes Mitotic Slippage and Contributes to Drug Resistance in Paclitaxel-Treated Cancer Cells.

Authors:  Yue He; Daoyu Yan; Dianpeng Zheng; Zhiming Hu; Hongwei Li; Jinlong Li
Journal:  PLoS One       Date:  2016-09-09       Impact factor: 3.240

Review 5.  Insight into norcantharidin, a small-molecule synthetic compound with potential multi-target anticancer activities.

Authors:  Mu-Su Pan; Jin Cao; Yue-Zu Fan
Journal:  Chin Med       Date:  2020-05-29       Impact factor: 5.455

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.